Analyzing Sartorius Stedim Biotech (OTCMKTS:SDMHF) and Cresco Labs (OTCMKTS:CRLBF)

Cresco Labs (OTCMKTS:CRLBF) and Sartorius Stedim Biotech (OTCMKTS:SDMHF) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Earnings & Valuation

This table compares Cresco Labs and Sartorius Stedim Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cresco Labs	$655.85 million	0.49	-$135.41 million	($0.39)	-1.65
Sartorius Stedim Biotech	N/A	N/A	N/A	$4.31	44.78

Sartorius Stedim Biotech has lower revenue, but higher earnings than Cresco Labs. Cresco Labs is trading at a lower price-to-earnings ratio than Sartorius Stedim Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Cresco Labs and Sartorius Stedim Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cresco Labs	0	1	0	1	3.00
Sartorius Stedim Biotech	0	1	1	0	2.50

Institutional & Insider Ownership

0.1% of Cresco Labs shares are owned by institutional investors. Comparatively, 9.2% of Sartorius Stedim Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cresco Labs and Sartorius Stedim Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cresco Labs	-20.90%	-17.98%	-4.29%
Sartorius Stedim Biotech	N/A	N/A	N/A

Summary

Sartorius Stedim Biotech beats Cresco Labs on 7 of the 10 factors compared between the two stocks.

About Cresco Labs

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.